Univariate (Unadjusted) | OR (95% CI) | P |
---|---|---|
Baseline aPL profile | ||
Triple aPL positive | 0.25 (0.10–0.64) | 0.004 |
Double aPL positivea | 0.67 (0.31–1.46) | 0.32 |
Isolated LAC test positivity | 3.30 (1.53–7.13) | 0.002 |
Isolated aCL IgG/M positivityb,c | 2.13 (0.71–6.37) | 0.18 |
Isolated anti-β2-GPI IgG/M positivityb,c | 2.31 (0.49–10.75) | 0.29 |
Baseline individual aPL tests | ||
LAC test positivity | 0.21 (0.11–0.41) | < 0.001 |
aCL IgG ≥ 40 U | 0.21 (0.10–0.45) | < 0.001 |
aCL IgM ≥ 40 U | 0.26 (0.09–0.73) | 0.01 |
anti-β2-GPI IgG ≥ 40 U | 0.26 (0.11–0.65) | 0.004 |
anti-β2-GPI IgM ≥ 40 U | 0.28 (0.08–0.93) | 0.04 |
Age | 1.27 (0.98–1.63) | 0.06 |
Sex, male | 0.70 (0.33–1.48) | 0.35 |
HCQ use | 0.94 (0.47–1.87) | 0.85 |
Autoimmune disease | 1.27 (0.60–2.67) | 0.54 |
Active smoking | 1.56 (0.32–7.53) | 0.58 |
Multivariable (Adjusted) | OR (95% CI) | P |
Baseline aPL profile | ||
Triple aPL positived | 0.17 (0.07–0.39) | < 0.0001 |
Isolated LAC test positivityd | 3.65 (1.94–6.84) | < 0.0001 |
Isolated anti-β2-GPI positivityd | 4.17 (1.24–14.1) | 0.02 |
Baseline individual aPL tests | ||
LAC test positivitye | 0.26 (0.10–0.66) | 0.005 |
aCL IgG ≥ 40 Uf | 0.24 (0.09–0.66) | 0.006 |
Values in bold are statistically significant.
↵aAny combination of 2 posi- tive aPL tests based on the laboratory criteria of the Updated Sapporo APS Classification Criteria.
↵bAny titer above normal range.
↵cThe small number of patients in isolated aCL and anti-β2-GPI aPL profile categories precluded from further analysis of isolated IgG or IgM isotype for these groups.
↵d Adjusted for age, sex, active smoking, concomitant autoimmune disease, and HCQ use at baseline.
↵eAdjusted for age, sex, active smoking, concomitant autoimmune disease, HCQ use at baseline, clinically meaningful (≥ 40 U) aCL IgG and IgM at baseline, and clinically meaningful (≥ 40 U) anti-β2-GPI IgG and IgM at baseline.
↵fAdjusted for age, sex, active smoking, concomitant autoimmune disease, HCQ use at baseline, LAC test result at baseline, clinically meaningful (≥ 40 U) aCL IgM at baseline, and clinically meaningful (≥ 40 U) anti-β2-GPI IgG and IgM at baseline. aCL: anticardiolipin antibody; anti-β2-GPI: anti-β glycoprotein I antibody; aPL: antiphospholipid antibody; APS: antiphospholipid syndrome; HCQ: hydroxychloroquine; LAC: lupus anticoagulant.